However, ovarian cancers with BRCA germline and somatic mutations are more sensitive to platinum-based therapy and Poly (ADP ribose) polymerase 1 (PARP)-inhibitors, and have better overall survival [7, 8]. Here, PARP1 is linked to ovarian carcinoma.